Maxim Pharmaceuticals Receives Approval From FDA of a Treatment Protocol for Ceplene in Advanced Malignant Melanoma
April 14, 2004 03:13 ET
|
Maxim Pharmaceuticals
SAN DIEGO, April 14, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination...
Maxim Pharmaceuticals Presents Preclinical Results For Its Novel Vascular Targeting Agent MX116407
March 30, 2004 02:49 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, and SAN DIEGO, March 30, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced research results demonstrating the anti-cancer activity of the Company's...
Maxim Pharmaceuticals Completes Phase 1 Pharmacokinetic Trial of Orally Dosed Histamine
March 23, 2004 03:07 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, March 23, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it has completed a Phase 1A pharmacokinetic trial of a new orally...
Maxim Pharmaceuticals Reacquires Rights To Mx2105 Preclinical Cancer Drug Candidate
March 17, 2004 03:01 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, March 17, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE: MAXM) today announced that it has entered into anagreement with Shire BioChem, Inc. under which Maxim has...
Maxim Pharmaceuticals Announces Publication of the Discovery and Characterization of Potent Anti-Cancer Compound
February 12, 2004 03:12 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced the publication of its manuscript entitled "Discovery, Characterization and SAR of Gambogic...